IRLAB Therapeutics: Further positive phase I results with IRL757 - Redeye

Redeye comments on the positive phase I results for IRL757 announced by IRLAB. We are encouraged to learn that the study confirmed strong safety, tolerability, and pharmacokinetic properties, supporting progression to a fully funded phase Ib trial in apathy patients later this year. We believe that this represents an important milestone in the development of IRL757.

Länk till analysen i sin helhet: https://www.redeye.se/research/1113177/irlab-therapeutics-further-positive-phase-i-results-with-irl757?utm_source=finwire&utm_medium=RSS